Afrigen Biologics and Vaccines: International Licensing or Acquisition?

Name: Afrigen Biologics and Vaccines: International Licensing or Acquisition? (English version)
SKU: W41360

Abiodun E. Awosusi, Paul W. Beamish, Vanessa C. Hasse, Ning Su

Product #:W41360

Supplier:Ivey

Discipline:International Business, Strategy

Setting:2024

Details:Case (PDF) • 14 pages • 2024-11-26

Subjects:

Business management International business Strategy

Industries:

Healthcare sector

Your Price:

$10.54

Purchase this material with a free Educator Account and enjoy more benefits:

Free Educator Copy
Free Teaching Notes
Build your coursepack
Discounted academic price

Afrigen Biologics (Pty) Ltd. (Afrigen) was a biotech firm with a track record of solid performance in the sector with its leadership in sharing mRNA technology and developing a vaccine for COVID-19. By August 2024, with the threat of the COVID-19 pandemic under control, the firm was ready to capitalize on its track record and pivot. Petro Terblanche, CEO of Afrigen, needed to decide, therefore, what the firm’s next steps would be. What should the company's new business model be after the end of the current mRNA technology transfer program? How could Afrigen position itself in the African biopharmaceutical value chain? How could it leverage its existing alliances? Should Afrigen pursue international licensing or position itself to be acquired?

Learning Objectives

The case can be used in undergraduate and graduate courses on health care management, strategic management, international business, and technology management to meet the following objectives:

Understand the importance of value chain analysis in the pharmaceutical industry.
Reflect on the role of technology transfer across the biopharmaceutical value chain.
Analyze the evaluation criteria for a health technology transfer program.
Analyze strategic options for biotech positioning and growth in emerging markets.